Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma

Table 1 Baseline characteristics of the patients

Patient (n)	28
Male/female	21/7
Portal thrombi (+/–)	7/21
TNM classification (II/III/IV)	5/11/12
Albumin	3.4±0.1 (g/dL)
Total bilirubin	1.3±0.2 (mg/dL)
ALT	48.2±6.4 (IU/L)
Platelet	11.3±1.7 (×104/mL)
PT	70.9±2.8 (%)
AFP	7 105±2 756 (ng/mL)
PIVKA-II	11 922±4 274 (U/L)

ALT, alanine aminotransferase; PT, prothrombin time; AFP, alpha-fetoprotein.

Table 2 Evaluation of IFNα /5-FU combination therapy

	Evaluation after 1st cyclepatient n (%)	Final resultspatient n (%)
CR		1 (3.6)
PR	16 (57.1)	5 (17.9)
NR	12 (42.9)	22 (78.6)

IFN, interferon; FU, fluorouracil; CR, complete response; PR, partial response; NR, no response.